Header Logo

Connection

John Zajecka to Humans

This is a "connection" page, showing publications John Zajecka has written about Humans.
Connection Strength

0.426
  1. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J Clin Psychiatry. 2016 May; 77(5):654-60.
    View in: PubMed
    Score: 0.040
  2. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013 Apr; 74(4):407-14.
    View in: PubMed
    Score: 0.032
  3. Evidence for the use of l-methylfolate combined with antidepressants in MDD. J Clin Psychiatry. 2011 Aug; 72(8):e25.
    View in: PubMed
    Score: 0.029
  4. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44.
    View in: PubMed
    Score: 0.026
  5. Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry. 2007; 68 Suppl 10:23-7.
    View in: PubMed
    Score: 0.021
  6. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
    View in: PubMed
    Score: 0.017
  7. Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression. Neuromodulation. 2022 Apr; 25(3):316-326.
    View in: PubMed
    Score: 0.015
  8. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
    View in: PubMed
    Score: 0.015
  9. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov; 157(11):1873-5.
    View in: PubMed
    Score: 0.014
  10. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
    View in: PubMed
    Score: 0.013
  11. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245.
    View in: PubMed
    Score: 0.013
  12. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000; 61 Suppl 2:20-5.
    View in: PubMed
    Score: 0.013
  13. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
    View in: PubMed
    Score: 0.012
  14. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry. 1997; 58 Suppl 3:9-13; discussion 14-5.
    View in: PubMed
    Score: 0.010
  15. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997; 58 Suppl 7:5-10.
    View in: PubMed
    Score: 0.010
  16. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997; 58 Suppl 7:23-7.
    View in: PubMed
    Score: 0.010
  17. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997; 58 Suppl 7:37-40.
    View in: PubMed
    Score: 0.010
  18. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015 Jul; 40(8):2025-37.
    View in: PubMed
    Score: 0.009
  19. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct; 71(10):1157-64.
    View in: PubMed
    Score: 0.009
  20. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63.
    View in: PubMed
    Score: 0.009
  21. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec; 169(12):1267-74.
    View in: PubMed
    Score: 0.008
  22. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991 Feb; 52(2):66-8.
    View in: PubMed
    Score: 0.007
  23. Innovative somatic treatments for depression. Psychiatr Med. 1991; 9(1):77-103.
    View in: PubMed
    Score: 0.007
  24. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.007
  25. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990 Apr; 10(2):152-3.
    View in: PubMed
    Score: 0.007
  26. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
    View in: PubMed
    Score: 0.005
  27. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007 May 15; 25(10):1163-74.
    View in: PubMed
    Score: 0.005
  28. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06.
    View in: PubMed
    Score: 0.005
  29. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry. 2006 Nov; 67(11):1674-81.
    View in: PubMed
    Score: 0.005
  30. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006 Jan; 67(1):15-22.
    View in: PubMed
    Score: 0.005
  31. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.005
  32. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 01; 58(5):347-54.
    View in: PubMed
    Score: 0.005
  33. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
    View in: PubMed
    Score: 0.004
  34. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
    View in: PubMed
    Score: 0.004
  35. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003 Mar; 64(3):288-94.
    View in: PubMed
    Score: 0.004
  36. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
    View in: PubMed
    Score: 0.004
  37. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan; 62(1):12-8.
    View in: PubMed
    Score: 0.003
  38. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
    View in: PubMed
    Score: 0.003
  39. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.